Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 234 cancer 131 forskning & utveckling 115 hjärta/kärl 98 diabetes 64 andningsvägar 37 mage/tarm 14 neurovetenskap 12 FDA 10 astma 8 delårsrapport 8 onkologi 8 seroquel 7 infektion 7 forskning 7 Observationsstudie 6 medimmune 6 akut kranskärlssjudom 6 ledning 5 forxiga 5 influensavaccin 5 motavizumab 5 RWE 5 egfr-testning 5 bokslutsrapport 5 vandetanib 5 Tagrisso 5 naloxegol 5 bristol-myers squibb 4 fluenz 4 anders ekblom 4 ledgångsreumatism 4 antibiotika 4 fostamatinib 4 olaparib 4 karolinska institutet 4 seroquel xr 4 lungcancer 4 tc-5214 4 japan 3 osimertinib 3 CVD-REAL 3 styrelsen 3 egentlig depression 3 slusg 3 kroniskt obstruktiv lungsjukdom 3 astra tech 3 gefitinib 3 antibiotikaresistens 3 pathos 3 selumetinib 3 produkt 3 vimovo 3 crestor® 3 subvention 3 individanpassad behandling 2 kina 2 entocort 2 astrazenca 2 opioider 2 axanum 2 registerstudie 2 byetta 2 Real World evidence 2 återfall 2 patenttvist 2 corporate 2 tyskland 2 ardea biosciences 2 typ2diabetes 2 targacept 2 seroquel xl 2 acalabrutinib 2 seroquel xr (quetiapin fumarat) 2 almedalen 2 benralizumab 2 life science 2 ticagrelor 2 samarbete 2 bydureon 2 Brilique 2 saturn 2 epanova 2 mdd 2 läkemedelsförmånen 2 slusg stipendium 2 klopidogrel 2 fulvestrant 2 esc 2 confirm 2 smärta 2 caprelsa 2 recentin 2 kvartalsrapport 2 anastrozol 1 atac 1 bypass 1 kolorektalcancer 1 sjukhussjuka 1 avancerad bröstcancer 1 avastin 1 kvalitetsregister 1 blodförgiftning 1 ämnesomsättningssjukdomar 1 jupiter-studien 1 ämnesomsättningssjukdomar (emdac) 1 jupiter 1 faslodex (fulvestrant) 1 monoterapi 1 den amerikanska läkemedelsmyndigheten 1 skelettmetastaser 1 roger henriksson 1 produktionsanläggning 1 gikt 1 cardiologföreningen 1 ovarian cancer 1 merck-avtal 1 savor 1 årsredovisning 2010 1 non-executive director 1 iressa 1 nytt läkemedel mot lungcancer 1 behandling lungcancer 1 målstyrt läkemedel 1 EGFR 1 nytt läkemedel lungcancer 1 cediranib 1 bevacizumab 1 scilifelab 1 yngre forskare 1 päivi tolstoy 1 tobias ankner 1 hans andersson 1 syntetisk kemi 1 torrent pharma 1 varumärkta generika 1 saxagliptin 1 hypoglykemi 1 blodsockerkontroll 1 blodsockerfall 1 viktökning 1 ldl-c 1 gonorré 1 sepsis 1 livskvalitet lungcancer 1 ipass 1 lungcancersymtom 1 mcrc 1 complete response letter (crl) 1 u.s. food and drug administration (fda) 1 årets kvinnliga ledare 1 karin norlén 1 generiskt esomeprazolmagnesium 1 kanadensiska hälsovårdsministeriet 1 apotex inc (notice of compliance 1 noc) 1 internationell konkurrens 1 nikotinkanalsblockerare 1 läkemedel 1 DAISY 1 subventioner 1 UCR 1 zibotentan 1 vnr 1 pressmaterial 1 biokemiska markörer 1 egfr-muterad 1 cytofab 1 azd9773 1 eurika 1 kombiglyze xr 1 klinisk forsk 1 pegasus 1 produktionschef 1 berzeliussamlingen 1 nya läkemedel 1 right honourable baroness shriti vadera 1 certriad 1 astrazeneca lund 1 arbetsmarknadsdagar 1 registreringsansökan 1 kastrationsresistent 1 fas 3-studie 1 hormonresistent 1 budesonid 1 mobil-app 1 opioidbehandling 1 nktr-118 1 sustainable brands 2011 1 forskningsportfölj 1 skatteärende 1 denosumab 1 amylin 1 patologi 1 NSCLC 1 egfr mutation 1 egfr positiv 1 komboglyze 1 caz-avi 1 hälsoekonomiska data 1 delårsrapport januari-september 2011 1 patientundersökning 1 david brennan 1 hudinfektioner 1 medicon village 1 translationell 1 illumina 1 årsredovisning 2011 1 antibiotikum 1 flumist 1 kvadrivalent 1 quetiapin fumarat 1 citizen petitions 1 renaissance 4 1 renaissance 5 1 formuleringspatent 1 citizens petition 1 hjärtkärlhälsa 1 prismodell 1 lesinurab 1 the medicines company 1 nda 1 amend 1 amylin pharmaceuticals 1 mdr-tb 1 mikael agaton 1 grymt fett 1 tonårshjärnan 1 per hamid ghatan 1 grymt fett en filmserie om tonårshjärnan 1 exacerbationer 1 pascal soriot 1 säsongsinfluensavaccin för barn som nässpray 1 säsongsinfluencavaccin 1 barninfluensavaccin 1 nässprayvaccin 1 influensanässpray 1 jonas bergh 1 bröstcancer utmärkelse 2012 1 sjukhusinfektioner 1 zinforo 1 mjukdelsinfektioner 1 ceftarolinfosamil 1 max planck institute 1 magnus björsne 1 per alfredsson 1 remissvar prismodell 1 pris läkemedel 1 strategiska centra 1 forsknings - och utvecklingscentra 1 bioläkemedel 1 tre strategiska centra 1 aks 1 exenatide 1 glp-1 agonister 1 cancerregister 1 svenska lungcancerstudiegruppen 1 non-small-cell lungcancer 1 motivationsstöd 1 patient websida 1 sekundärprevention 1 patientstöd 1 fluenz tetra 1 metreleptin 1 lipodystrofi 1 lesinurad 1 farxiga 1 xigduo 1 myalept 1 ann cairns 1 akuta koronara syndrom 1 metabola sjukdomar 1 immunoterapier 1 advaxis 1 sommarforskarskola 1 non-small cell lung cancer 1 astma/kol 1 gensekvensering 1 oic 1 hjärt-och kärlsjukdom 1 hjärinfarkt 1 biohub 1 bioventurehub 1 elisabeth björk 1 antaros 1 hha 1 healthy heart africa 1 världsdiabetesdagen 2014 1 moventig 1 Lynparza 1 opioidorsakad 1 pegasus-timi 1 e-brilique 1 Uppsala Clinical Research Center 1 mobiltelefonapplikation 1 SUPPORT-studien 1 ordnat införande Almedalen 1 QTERN 1 Zavicefta 1 moderna therapeutics 1 SvFP 1 kyntheum 1 brodalumab 1 Imfinzi 1 durvalumab 1 CVD-REAL Nordic 1 osimertinub 1 världsastmadagen 1 PACEHR 1 svår astma 1 Katarina Ageborg 1 norge 1 VD AstraZeneca Sverige AB 1 innovation 1 eu 1 blogg 1 sponsring 1 hållbar utveckling 1 patent 1 produktion 1 lund 1 debatt 1 forskare 1 stipendier 1 usa 1 hjärtinfarkt 1 stroke 1 kol 1 skl 1 kemi 1 influensa 1 depression 1 antidepressiva läkemedel 1 tlv 1 beslut 1 alzheimers 1 äggstockscancer 1 lif 1 prevention 1 södertälje 1 alzheimers sjukdom 1 telekonferens 1 högkostnadsskyddet 1 collaboration 1 halvårsrapport 1 forskarstipendium 1 schizofreni 1 merck 1 dow jones sustainability index 1 läkemedelsforskning 1 läkemedelstillverkning 1 pfizer 1 psoriasis 1 anläggningar 1 bakterier 1 stöd 1 karolinska universitetssjukhuset 1 kronisk smärta 1 artros 1 pa 1 delårsrapport januari - mars 1 h1n1 1 r&d 1 mölndal 1 generiska läkemedel 1 typ 2-diabetes 1 styrelseordförande 1 gener 1 apollo 1 hälsoekonomi 1 socialminister 1 halvårsresultat 1 pet 1 mrsa 1 ny indikation 1 diagnostik 1 förstoppning 1 kranskärlsjukdom 1 invasiv behandling 1 journal of clinical oncology 1 avancerad hormonkänslig bröstcancer 1 first studien 1 dapagliflozin 1 asco 1 konkurrenskraften 1 läkemedelsforskningen 1 forskarkarriärer 1 stipendieprogram 1 rosuvastatinkalcium 1 hyperkolesterolemi 1 pluto-studien 1 vimovotm 1 nsaid 1 pozen 1 sumitomo 1 american college of rheumatology 1 2009 annual scientific meeting in philadelphia 1 leif johansson 1 zactima (vandetanib) 1 toprol-xl 1 vaccinet 1 inflammation 1 jan lundberg 1 stemi 1 rosuvastatin 1 arimidex 1 Visa alla taggar

Senaste nytt

AstraZeneca presents further data showing the interconnectivity between cardiovascular and renal risks in diabetes at EASD 2018

AstraZeneca presents further data showing the interconnectivity between cardiovascular and renal risks in diabetes at EASD 2018

Pressmeddelanden   •   Sep 20, 2018 12:26 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, will present more than 50 abstracts from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany, 1-5 October 2018.

Fasenra shows consistent safety and sustained efficacy in  long-term Phase III BORA trial in severe eosinophilic asthma

Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

Pressmeddelanden   •   Sep 18, 2018 08:04 CEST

AstraZeneca today announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed one of the two pivotal SIROCCO or CALIMA Phase III trials.

The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease

The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease

Pressmeddelanden   •   Sep 16, 2018 17:29 CEST

Data from the KRONOS trial presented at the European Respiratory Society (ERS) International Congress 2018

US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk)  for certain patients with relapsed or refractory hairy cell leukaemia

US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia

Pressmeddelanden   •   Sep 13, 2018 22:18 CEST

AstraZeneca and MedImmune, announced today that the US FDA has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.Lumoxiti is not recommended in patients with severe renal impairment (CrCl ≤ 29 mL/min).

AstraZeneca to present Fasenra long-term safety and efficacy data at European Respiratory Society International Congress 2018

AstraZeneca to present Fasenra long-term safety and efficacy data at European Respiratory Society International Congress 2018

Pressmeddelanden   •   Sep 13, 2018 08:04 CEST

AstraZeneca and MedImmune, today announced that new data from the BORA Phase III extension trial of Fasenra (benralizumab) is among 43 company abstracts accepted for oral and poster presentation at the European Respiratory Society (ERS) International Congress 2018, 15-19 September in Paris.

Tezepelumab granted Breakthrough Therapy Designation by US FDA

Tezepelumab granted Breakthrough Therapy Designation by US FDA

Pressmeddelanden   •   Sep 07, 2018 08:03 CEST

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.

Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus

Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus

Pressmeddelanden   •   Aug 31, 2018 08:04 CEST

AstraZeneca and MedImmune, today announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet the primary endpoint of a statistically-significant reduction in disease activity in patients with SLEas measured by the SLE Responder Index 4 (SRI4)at 12 months.

European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes

European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes

Pressmeddelanden   •   Aug 30, 2018 08:02 CEST

AstraZeneca today announced that the European Commission (EC) has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorisation for Bydureon (exenatide extended release) for the treatment of patients with type-2 diabetes.

AstraZeneca provides update on AERISTO Phase IIIb trial for  Bevespi Aerosphere in chronic obstructive pulmonary disease

AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstructive pulmonary disease

Pressmeddelanden   •   Aug 23, 2018 14:08 CEST

AstraZeneca today announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Tagrisso approved in Japan for 1st-line treatment of EGFR-mutated non-small cell lung cancer

Tagrisso approved in Japan for 1st-line treatment of EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Aug 21, 2018 08:01 CEST

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), following priority review.

AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

Pressmeddelanden   •   Aug 20, 2018 08:02 CEST

New evidence of the persistency of ischaemic risk in post-heart attack patients, highlighting specific risk factors that may help identify patients for extended DAPT Latest data on the links between RAAS inhibitor dose reduction and increased risk of mortality and MACE in heart failure patients with hyperkalaemia

Selumetinib granted orphan designation in Europe for neurofibromatosis type 1

Selumetinib granted orphan designation in Europe for neurofibromatosis type 1

Pressmeddelanden   •   Aug 03, 2018 08:19 CEST

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Imfinzi receives positive EU CHMP opinion for locally- advanced, unresectable non-small cell lung cancer

Imfinzi receives positive EU CHMP opinion for locally- advanced, unresectable non-small cell lung cancer

Pressmeddelanden   •   Jul 27, 2018 15:03 CEST

Recommended marketing authorisation for patients whose tumours express PD-L1 on ≥1% of tumour cells Imfinzi is the first immunotherapy recommended for approval for the treatment of locally-advanced, unresectable NSCLC

AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2018

AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2018

Pressmeddelanden   •   Jul 26, 2018 08:06 CEST

Starka resultat från nya läkemedel och tillväxtmarknaderna stödjer återgång till tillväxt under 2018

Atacand to be divested to Cheplapharm in Europe

Atacand to be divested to Cheplapharm in Europe

Pressmeddelanden   •   Jul 24, 2018 08:12 CEST

AstraZeneca has agreed to sell the commercial rights to Atacand(candesartan cilexetil)and AtacandPlus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to CheplapharmArzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension.

Katarina Ageborg ny VD för AstraZeneca i Sverige

Katarina Ageborg ny VD för AstraZeneca i Sverige

Pressmeddelanden   •   Jul 16, 2018 13:22 CEST

AstraZeneca meddelar i dag att Katarina Ageborg utsetts till ny VD för AstraZeneca AB. Hon tar över efter Jan-Olof Jacke den 1 augusti 2018 och kommer även fortsättningsvis rapportera till koncernchef Pascal Soriot.

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Pressmeddelanden   •   Jul 02, 2018 08:03 CEST

Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Second approval in Japan for AstraZeneca and MSD’s Lynparza

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

Pressmeddelanden   •   Jul 02, 2018 08:02 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC).

Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes

Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes

Pressmeddelanden   •   Jun 29, 2018 16:09 CEST

AstraZeneca today announced that the CHMP of the European Medicines Agency (EMA) has adopted a positive opinion, recommending inclusion of Bydureon (2mg prolonged-release suspension for injection) BCise device as a new formulation within the marketing authorisation for Bydureon (exenatide extended-release) for the treatment of type-2 diabetes.

Lynparza significantly delays disease progression in Phase III  1st-line SOLO-1 trial for ovarian cancer

Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer

Pressmeddelanden   •   Jun 27, 2018 08:02 CEST

AstraZeneca and MSD today announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.